Market Research Industry Today
Non-invasive Prenatal Testing Market to Reach USD 13.2 Billion by 2035, Expanding at 9.5% CAGR - TMR
The global non-invasive prenatal testing (NIPT) market was valued at US$ 4.7 Bn in 2024. The market is projected to expand at a CAGR of 9.5% from 2025 to 2035, reaching approximately US$ 13.2 Bn by the end of 2035.
Growing awareness of prenatal screening, increasing maternal age, and the rising risk of fetal chromosomal abnormalities are supporting demand for NIPT worldwide. The increasing preference for safe and early screening methods is also encouraging physicians and expectant parents to adopt cell-free DNA-based testing over conventional screening approaches.
Explore pivotal insights and conclusions from our Report in this sample -
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=374
Market Overview
Non-invasive prenatal testing is a prenatal screening procedure used to assess the risk of selected genetic and chromosomal conditions in a fetus. The test analyzes small fragments of fetal DNA circulating in the mother's blood and can generally be performed as early as the 10th week of pregnancy.
Unlike invasive procedures such as amniocentesis and chorionic villus sampling (CVS), NIPT requires only a maternal blood sample and does not involve direct physical intervention with the fetus. This safety advantage, combined with high screening accuracy and the ability to identify chromosomal abnormalities early in pregnancy, has increased the adoption of NIPT across healthcare systems.
NIPT is primarily used to screen for chromosomal conditions such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13). Depending on the test, it can also provide information related to sex chromosome abnormalities and fetal sex. Advances in sequencing technologies are further expanding the scope of prenatal genetic screening.
The market is also benefiting from strategic collaborations among NIPT providers, diagnostic laboratories, healthcare institutions, and technology companies. Increasing competition and the expansion of reimbursement coverage in several countries are creating additional opportunities for market participants.
Key Market Growth Drivers
Rising Prevalence of Down Syndrome Cases
The prevalence of chromosomal disorders, including Down syndrome and Turner syndrome, is a major factor contributing to demand for NIPT. The high screening accuracy and non-invasive nature of NIPT make it an attractive alternative to conventional prenatal screening and invasive diagnostic procedures.
Traditional screening approaches, including nuchal translucency scans and maternal serum screening, are non-invasive but generally have lower detection accuracy than DNA-based screening. In contrast, invasive procedures such as amniocentesis and CVS can provide highly accurate diagnostic results but carry a risk of complications, including miscarriage. Consequently, many expectant parents and physicians are increasingly considering NIPT as an important step in prenatal screening.
Commercial tests such as MaterniT21 PLUS, Harmony, Verifi, Panorama, and NIFTY have contributed to the wider availability of NIPT for screening chromosomal abnormalities.
According to Down Syndrome Education International, the prevalence of Down syndrome varies across countries, ranging from approximately 1 in 1,500 to 1 in 400 live births. The organization has also reported that approximately 220,000 babies are born with Down syndrome globally each year. In the U.S., the Centers for Disease Control and Prevention (CDC) estimates an incidence of approximately 1 in every 700 births, equivalent to around 6,000 births annually.
The continuing need to identify chromosomal abnormalities during pregnancy is therefore expected to support adoption of advanced prenatal screening technologies.
Growing Maternal Age and Associated Chromosomal Risks
Increasing maternal age is another important factor supporting growth of the NIPT market. The average age of first-time mothers has risen in several developed countries, including the U.S., U.K., France, Germany, Italy, and Japan. Financial considerations, higher education levels, career priorities, and broader social changes have contributed to this trend.
Maternal age is associated with an increasing risk of fetal chromosomal abnormalities. According to the American Academy of Family Physicians (AAFP), the risk of fetal chromosomal abnormalities rises gradually through approximately age 30 and increases more rapidly thereafter. The reported probability of Down syndrome is approximately 1 in 1,300 at age 25, increasing to 1 in 365 at age 35 and approximately 1 in 30 after age 40.
The increase in pregnancies among older mothers is consequently expanding the population that may seek prenatal chromosomal screening. NIPT's ability to provide early screening through a maternal blood sample is expected to strengthen its adoption among both healthcare providers and expectant parents.
Diagnostic Laboratories Segment to Expand Rapidly
Based on end-user, the global non-invasive prenatal testing market is segmented into hospitals, specialty clinics, diagnostic laboratories, and others, including research institutes.
The diagnostic laboratories segment is expected to expand at a significant rate during the forecast period. Expansion of diagnostic infrastructure and the increasing availability of specialized genetic testing services are allowing laboratories to serve a growing number of pregnant women seeking prenatal screening.
The presence of specialized laboratories offering NIPT is further contributing to market development. For instance, MedGenome Labs Ltd. offers the MedGenome Claria NIPT test for screening trisomies 21, 18, and 13, monosomy X, and other sex chromosome abnormalities.
MedGenome's Claria NIPT Plus additionally screens for conditions including Down syndrome, Edwards syndrome, Patau syndrome, triploidy, Turner syndrome, Klinefelter syndrome, Triple X syndrome, Jacob's syndrome, 22q11.2 deletion syndrome, 1p36 deletion syndrome, Prader-Willi syndrome, Angelman syndrome, and Cri-du-chat syndrome.
The increasing availability of broader prenatal screening panels through diagnostic laboratories is expected to support the segment's growth and improve access to NIPT services.
Access detailed insights by visiting our full report -
https://www.transparencymarketresearch.com/noninvasive-prenatal-diagnostics-market.html
Regional Outlook
North America Leads the Market
North America dominated the global non-invasive prenatal testing market with approximately 60% share in 2024, followed by Europe. The region's leading position is supported by advanced healthcare infrastructure, high awareness of prenatal screening, widespread availability of genetic testing services, and the presence of major NIPT companies in the U.S.
The high rate of diagnosis and screening for trisomy disorders, combined with established healthcare systems and the increasing adoption of advanced sequencing technologies, is contributing to regional market expansion.
Product innovation is also supporting market development. In May 2024, Natera, Inc. launched a cell-free DNA (cfDNA)-based fetal RhD test designed to determine fetal RhD status from a maternal blood sample as early as nine weeks of gestation. The company reported 100% sensitivity and more than 99% specificity in a validation study involving more than 650 RhD-negative pregnancies.
Asia Pacific to Witness Rapid Growth
The Asia Pacific non-invasive prenatal testing market is projected to register the fastest CAGR during the forecast period. Rising maternal age across several countries is contributing to an expanding population at risk of fetal chromosomal abnormalities, thereby increasing the potential demand for prenatal screening.
China and Japan are witnessing significant advancements in prenatal genetic testing, while the broader region is benefiting from improvements in healthcare infrastructure and the integration of next-generation sequencing (NGS) technologies.
Increasing awareness among expectant parents, improved access to specialized diagnostic services, and technological advances in genomic testing are expected to further support NIPT adoption across Asia Pacific.
Analysis of Key Players and Key Player Strategies
The non-invasive prenatal testing market is relatively consolidated, with established companies competing through broad product portfolios, advanced genomic technologies, extensive distribution networks, and strategic collaborations.
Companies are pursuing partnerships, product launches, technology development, and portfolio expansion to strengthen their presence in both developed and emerging markets. Improvements in sequencing platforms and the expansion of testing panels are also enabling market participants to address a broader range of chromosomal and genetic conditions.
Key companies profiled in the market include Berry Genetics, BGI, Laboratory Corporation of America Holdings, Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd., Natera, Inc., PerkinElmer Inc., Eurofins Scientific, and IGENOMIX, along with other market participants.
Key Developments
In February 2025, Yourgene Health, part of the Novacyt group, announced the launch of IONA Care+ in the U.K. The service uses Yourgene's IONA Nx NIPT workflow to provide non-invasive prenatal testing results. The offering is intended to provide expectant parents with an alternative to invasive testing and associated risks while supporting faster access to screening results.
In May 2024, Natera, Inc. announced the launch of a new cfDNA-based fetal RhD test. The test can be performed from nine weeks of gestation and determines fetal RhD status from a pregnant patient's blood sample. The company highlighted the test's ability to identify complex pseudogene and RhD-CE-D hybrid variants, positioning fetal RhD assessment as a differentiating capability within the NIPT market.
Market Challenges and Opportunities
Despite strong growth prospects, NIPT adoption remains influenced by factors such as testing costs, reimbursement availability, regulatory requirements, and differences in healthcare infrastructure between developed and emerging markets. Access to advanced genetic testing remains uneven across countries, while healthcare providers also require appropriate genetic counseling and clinical interpretation to ensure that screening results are correctly understood.
At the same time, the increasing adoption of genomic technologies presents substantial opportunities. Whole-genome sequencing, SNP analysis, microarray analysis, and other molecular techniques are enabling providers to expand the scope of prenatal screening. Increasing maternal age, greater awareness of genetic conditions, and the expansion of diagnostic laboratory networks are expected to create additional opportunities for NIPT providers.
Growing reimbursement coverage and government-supported prenatal screening programs could further increase accessibility, particularly in markets where NIPT is transitioning from a specialized service toward a more broadly available prenatal screening option.
Investment Landscape and ROI Outlook
The NIPT market presents investment opportunities across genomic testing platforms, sequencing technologies, laboratory infrastructure, test kits, reagents, and specialized diagnostic services. Investments in automated laboratory workflows and advanced bioinformatics can help testing providers improve throughput and expand their testing portfolios.
Strategic partnerships between diagnostic laboratories and technology providers can also support market penetration by combining laboratory capabilities with established genomic platforms and distribution networks. As demand for early and non-invasive prenatal screening continues to expand, companies capable of providing accurate, scalable, and accessible testing solutions are positioned to participate in the market's long-term expansion.
Non-invasive Prenatal Testing Market Segmentation
The global non-invasive prenatal testing market is segmented as follows:
By Test Type: Cell-Free DNA Screening Test, Serum Marker Screening Test, Neural Tube Defects Test, and Ultrasonography.
By Product: Instruments and Kits & Reagents.
By Technology: Whole-Genome Sequencing, SNP Analysis, Microarray Analysis, and Rolling Circle Amplification.
By Indication: Down Syndrome (trisomy 21), Edwards Syndrome (trisomy 18), Patau Syndrome (trisomy 13), Turner Syndrome (Monosomy X/XO), Klinefelter Syndrome (XXY), Jacob's Syndrome (XYY), Gender Identification, and Others, including Triple X syndrome.
By End-user: Hospitals, Specialty Clinics, Diagnostic Laboratories, and Others, including Research Institutes.
By Region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Countries Covered: U.S., Canada, Germany, U.K., France, Italy, Spain, China, India, Japan, Australia & New Zealand, Brazil, Mexico, GCC Countries, and South Africa.
Why Buy This Report?
The report provides comprehensive analysis of the global non-invasive prenatal testing market, covering market size, growth trends, competitive dynamics, technological developments, and regional opportunities. It includes quantitative market analysis in US$ Bn and examines the market across major product, test type, technology, indication, end-user, and regional segments.
The report also provides company profiles covering business overview, product portfolio, geographic presence, subsidiaries or distributors, business strategies, recent developments, and key financial information. The study includes historical data for 2020–2023 and forecasts the market through 2035.
FAQs
What was the size of the non-invasive prenatal testing market in 2024?
The global non-invasive prenatal testing market was valued at approximately US$ 4.7 Bn in 2024.
What is the projected size of the NIPT market by 2035?
The market is expected to reach approximately US$ 13.2 Bn by the end of 2035.
What CAGR is expected for the non-invasive prenatal testing market?
The market is projected to expand at a 9.5% CAGR from 2025 to 2035.
Which region dominated the NIPT market in 2024?
North America dominated the market, accounting for approximately 60% share in 2024.
Which region is expected to record the fastest growth?
Asia Pacific is projected to register the fastest CAGR during the forecast period, supported by increasing maternal age, advances in genomic technologies, and improvements in healthcare infrastructure.
Buy this Premium Research Report and access vital insights and analysis -
https://www.transparencymarketresearch.com/checkout.php?rep_id=374<ype=S
More Trending Reports by Transparency Market Research -
GCC Countries Vertical Lift Module Market
Computed Tomography (CT) Market
Atomic Force Microscopes (AFM) Market
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Media Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com
Share on Social Media
Contact Information
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street,
Suite 700
Albany NY
New York
12207
+1-518-618-1030
https://www.transparencymarketresearch.com
Other Industry News
Ready to start publishing
Sign Up today!
